Characterization of the Clinical-epidemiological Profile of Patients With SMA5q Types II and III: Observational Study

Key facts

Sponsor

Hospital Israelita Albert Einstein

Principal Investigator

Otávio Berwanger, PhD

Hospital Israelita Albert Einstein

Intervention

Nusinersen Injectable Product(drug)

Enrollment

155 enrolled

Eligibility

All sexes

Timeline

2020 – 2021

Study locations (9)

• Universidade Federal de Minas Gerais - Hospital das Clínicas, Belo Horizonte, Brazil
• Hospital de Clínicas da Universidade Estadual de Campinas - Unicamp, Campinas, Brazil
• Associação Hospitalar de Prot Infancia Dr Raul Carneiro - Hospital Infantil Pequeno Príncipe, Curitiba, Brazil
• Hospital Infantil Dr. Albert Sabin, Fortaleza, Brazil
• Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
• Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil
• Instituto de Puericultura e Pediatria Martagão Gesteira da Universidade Federal do rio de Janeiro - UFRJ, Rio de Janeiro, Brazil
• Hospital das Clínicas da Faculdade de Medicina de São Paulo - HCFMUSP, São Paulo, Brazil
• Universidade Federal de São Paulo, São Paulo, Brazil

Collaborators

Ministry of Health, Brazil

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Autosomal dominant adult-onset proximal spinal muscular atrophy

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07521930
  Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
  Johns Hopkins University
• ACTIVE NOT RECRUITINGNANCT07547189
  Effects of Developmental Support for Mothers of Infants With Spinal Muscular Atrophy
  Medipol University
• RECRUITINGPHASE3NCT07444476
  A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam
  Biogen
• RECRUITINGPHASE2NCT07047144
  A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
  Scholar Rock, Inc.
• RECRUITINGNCT07321990
  Study of the Reproducibility of the French Version of the Modified SMAFRS Scale
  Institut de Myologie, France
• ACTIVE NOT RECRUITINGNANCT06419322
  Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal Muscular Atrophy (SMA).
  University of Oxford
• ACTIVE NOT RECRUITINGNANCT06300996
  Spinal Cord Stimulation for the Treatment of Motor Deficits in People With Spinal Muscular Atrophy - Upper Limb
  Marco Capogrosso
• RECRUITINGNANCT06322654
  A Head-to-head Study Comparing the Functional Value of Two Models of Robotically Assisted Rehabilitation in SMA (Spinal Muscular Atrophy) Patients
  Wiktor Dega University Orthopedic and Rehabilitation Hospital

See all trials for Autosomal dominant adult-onset proximal spinal muscular atrophy →